Background: oral medications for the treatment of hepatitis C virus (HCV) infection, direct-acting antiviral agents (DAAs) are recommended. Worldwide, DAAs-based regimens have achieved excellent cure rates with a respectable profile of safety and a higher sustained virological response (SVR) rate than earlier interferon-containing therapy combinations. SVR is not achieved in about 5% of HCV patients on DAAs medications. Sofosbuvir, velpatasvir, and voxilaprevir (SOF/VEL/VOX) is the recommended retreatment regimen after prior first line DAA failure. Therefore, the purpose of this study was to assess the effectiveness, safety and biochemical changes of using Velpatasvir containing regimen (vosevi) for 12 weeks in the studied population.

Methodology: A prospective cohort study included 102 patients who had failed treatment with combination therapy (sofosbuvir and daclatasvir). Patients were recruited from the liver center at El-fayoum health insurance. They were subjected to the DAA regimen (SOF/VEL/VOX). Laboratory tests were evaluated at baseline, 4 weeks, 8 weeks, end of treatment, and 12 weeks after treatment.

Results: Our study showed that, after 12 weeks of treatment, 99 patients (97.1%) had a complete virologic response while 3 (2.9%) patients did not reach SVR12. In addition, mild side effects were detected in only 23.5% while the rest showed no adverse effects. Liver function tests during treatment and at SVR12 showed a considerable improvement.

Conclusion: Vosevi is an effective treatment for HCV patients who need to be treated again in Egypt with mild side effects.